Companies

Bharat Biotech, Thomas Jefferson University ink deal to develop Covid-19 vaccine candidate

Our Bureau Hyderabad | Updated on May 20, 2020 Published on May 20, 2020

Hyderbad-headquartered vaccine-maker Bharat Biotech and Thomas Jefferson University of Philadelphia have signed an exclusive deal to develop a new vaccine candidate for Covid-19 invented at Jefferson.

The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.

Infectious diseases expert Matthias Schnell’s lab developed the vaccine in January and recently completed preliminary tests in animal models.

The vaccine showed a ‘strong’ antibody response in mice receiving it. The researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection, with results expected next month.

Under the licence agreement, Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson’s vaccine across the world excluding the, Europe, Japan, etc, where Jefferson continues to seek partners.

With support from the Department of Biotechnology, Bharat Biotech aims to get into human trials as soon as December 2020.

“Our partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,” said Schnell, who directs The Jefferson Vaccine Institute and chairs Jefferson’s Department of Microbiology and Immunology,

“We will be able to complete animal testing and move to phase 1 clinical trial rapidly” he added.

Krishna Mohan, Chief Executive Officer of Bharat Biotech said: “We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases.”

Published on May 20, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.